XVIVO

XVIVO Perfusion AB is a publicly traded Swedish medtech leader with a mission to ensure 'nobody should die waiting for a new organ.' The company has achieved commercial success by establishing its machine perfusion devices and PERFADEX® Plus solution as standards of care in lung transplantation and expanding into kidney and liver preservation. Its strategy focuses on leveraging its integrated hardware-and-chemistry platform to expand into new organ types, like the heart, and deepen its service offerings to become a full-service partner to transplant centers worldwide.

Integrated ex-vivo machine perfusion platform for the preservation, assessment, and transport of donor organs, combining proprietary hardware devices, single-use disposables, and preservation solutions like PERFADEX® Plus.

XVIVO is a dominant leader in lung preservation and a strong competitor in liver/kidney. It faces competition from TransMedics (OCS), OrganOx, and Bridge to Life. XVIVO's key advantages are its multi-organ platform, protocol flexibility, and the high-margin, recurring revenue from its PERFADEX® Plus solution.